COMMUNIQUÉS West-GlobeNewswire
-
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
26/01/2026 -
Hapbee Appoints Marketing Expert Bally Singh to Board of Directors to Spearhead Global Brand Evolution
26/01/2026 -
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
26/01/2026 -
Da Vinci 5 Cleared for Cardiac Procedures
26/01/2026 -
Quantum Brainwave Protocol Product Information Updated as Consumer Interest in Digital Audio Relaxation Programs Grows in 2026
26/01/2026 -
Health-ISAC 2026 Report Details Rising Cyber Threats Across Health Sector
26/01/2026 -
DoseSpot's pVerify Achieves Multiple 2025 Recognitions from Gartner Digital Markets' Capterra, Software Advice and GetApp
26/01/2026 -
Purely Me Skin Tag Remover Product Information Updated as Consumer Interest in At-Home Skin Tag Solutions Grows in 2026
26/01/2026 -
New Clinical Data Demonstrate that VIVUS’ QSYMIA® in Combination with Digitally Enhanced Lifestyle Interventions (DELI) Leads to Significantly Greater Reductions in Weight and Cardiovascular Risk Compared with DELI Alone in Adults with Obesity
26/01/2026 -
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
26/01/2026 -
BlueOcean Global Announces FDA 510(k) Clearance of the Excelsior™ External Fixation System
26/01/2026 -
Primmune Therapeutics Announces Additional Close of Series B Financing
26/01/2026 -
Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors
26/01/2026 -
Leios Therapeutics and BNC Korea Announce Strategic Collaboration to Accelerate Development of 10XB-101 in South Korea
26/01/2026 -
Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
26/01/2026 -
GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures
26/01/2026 -
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program
26/01/2026 -
Invention of DNA "Page Numbers" Opens Up Vast Possibilities for the Bioeconomy
26/01/2026 -
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™
26/01/2026
Pages